J
Jennifer A. Lo
Researcher at Harvard University
Publications - 23
Citations - 2467
Jennifer A. Lo is an academic researcher from Harvard University. The author has contributed to research in topics: Melanoma & Immune checkpoint. The author has an hindex of 12, co-authored 23 publications receiving 1793 citations. Previous affiliations of Jennifer A. Lo include Oregon Health & Science University & Beth Israel Deaconess Medical Center.
Papers
More filters
Journal ArticleDOI
In vivo CRISPR screening identifies Ptpn2 as a cancer immunotherapy target
Robert T. Manguso,Robert T. Manguso,Hans W. Pope,Hans W. Pope,Margaret D. Zimmer,Margaret D. Zimmer,Flavian D. Brown,Kathleen B. Yates,Kathleen B. Yates,Brian C. Miller,Brian C. Miller,Natalie B. Collins,Natalie B. Collins,Natalie B. Collins,Kevin Bi,Kevin Bi,Martin W. LaFleur,Vikram R. Juneja,Sarah A. Weiss,Jennifer A. Lo,David E. Fisher,Diana Miao,Diana Miao,Eliezer M. Van Allen,Eliezer M. Van Allen,David E. Root,Arlene H. Sharpe,Arlene H. Sharpe,John G. Doench,W. Nicholas Haining,W. Nicholas Haining,W. Nicholas Haining +31 more
TL;DR: Deletion of the protein tyrosine phosphatase PTPN2 in tumour cells increased the efficacy of immunotherapy by enhancing interferon-γ-mediated effects on antigen presentation and growth suppression, and a pooled in vivo genetic screening approach using CRISPR–Cas9 genome editing is used to discover previously undescribed immunotherapy targets.
Journal ArticleDOI
An ultraviolet-radiation-independent pathway to melanoma carcinogenesis in the red hair/fair skin background
Devarati Mitra,Xi Luo,Ann M. Morgan,Jin Wang,Mai P. Hoang,Jennifer A. Lo,Candace R. Guerrero,Jochen K. Lennerz,Martin C. Mihm,Jennifer A. Wargo,Kathleen C. Robinson,Suprabha P. Devi,Jillian C. Vanover,John A. D'Orazio,Martin McMahon,Marcus Bosenberg,Kevin M. Haigis,Daniel A. Haber,Yinsheng Wang,David E. Fisher +19 more
TL;DR: The data suggest that the pheomelanin pigment pathway produces ultraviolet-radiation-independent carcinogenic contributions to melanomagenesis by a mechanism of oxidative damage, which suggests protection from ultraviolet radiation remains important, and additional strategies may be required for optimal melanoma prevention.
Journal ArticleDOI
Intratumoral Activity of the CXCR3 Chemokine System Is Required for the Efficacy of Anti-PD-1 Therapy.
Melvyn T. Chow,Aleksandra J. Ozga,Rachel L. Servis,Dennie T. Frederick,Jennifer A. Lo,David E. Fisher,Gordon J. Freeman,Genevieve M. Boland,Andrew D. Luster +8 more
TL;DR: The data suggest that the CXCR3 chemokines system is a biomarker for sensitivity to PD-1 blockade and that augmenting the intratumoral function of this chemokine system could improve clinical outcomes.
Journal ArticleDOI
The melanoma revolution: from UV carcinogenesis to a new era in therapeutics.
Jennifer A. Lo,David E. Fisher +1 more
TL;DR: An overview of recent developments in understanding of melanoma risk factors, genomics, and molecular pathogenesis and how these insights have driven advances in melanoma treatment is provided.
Journal ArticleDOI
Response to BRAF Inhibition in Melanoma Is Enhanced When Combined with Immune Checkpoint Blockade
Zachary A. Cooper,Vikram R. Juneja,Peter T. Sage,Dennie T. Frederick,Adriano Piris,Devarati Mitra,Jennifer A. Lo,F. Stephen Hodi,Gordon J. Freeman,Marcus Bosenberg,Martin McMahon,Keith T. Flaherty,David E. Fisher,Arlene H. Sharpe,Jennifer A. Wargo +14 more
TL;DR: Combining BRAF and PD-1/PD-L1 blockade slowed tumor growth and prolonged survival in a melanoma mouse model, with increased number and activity of tumor-infiltrating lymphocytes similar to that in a human melanoma patient treated with this regimen.